

Antimicrobial Susceptibility Test Results for Gram-positive isolates recovered from all sites: 2022

Organism Name	Antibiotics in common use (1st line reporting)											Reserved	Topical
	Number tested	Ampicillin/ amoxicillin	Penicillin	Meth/Flucloxacillin	Erythromycin	Clindamycin #	Gentamicin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim + sulfamethoxazole	Vancomycin #		
<i>S. aureus</i> (not MRSA)	536		25	100 ^a	92	93	99			100		98	96
MRSA	26		0	0	85	88	96			96			
<i>S. saprophyticus</i>	51	100		100				100	94	98			
<i>Enterococcus faecalis</i> /spp ^b	59	100						100			100		
<i>Enterococcus faecium</i>	3												
<i>Streptococcus pneumoniae</i>	7												

Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from all sites: 2022

Organism Name	Antibiotics in common use (1st line reporting)										Reserved (2nd line reporting)			
	Number tested	Ampicillin/ amoxicillin	Amoxicillin-Clavulanate	Cefuroxime IV	Cefalexin ^d	Gentamicin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim + sulfamethoxazole	Tetracycline	Ceftriaxone	Ciprofloxacin [#]	Meropenem [#]	Piperacillin-Tazobactam ^{\$}
<i>Escherichia coli</i>	703	67	82		97	98	99	87	87		98	92	100	100
ESCAPM group	38	0	0		0	97		83	94		92	97	100	89
<i>Klebsiella oxytoca</i>	38	0	97		97	100		97	100		97	97	100	97
<i>Klebsiella pneumoniae</i>	54	0	89		96	97		96	97		98	97	100	100
<i>Proteus mirabilis</i>	30	90	97		96	95		82	91		100	95	100	100
<i>Haemophilus influenzae</i>	41	80	88	89					73	100				
<i>Pseudomonas aeruginosa</i>	31											94	100	100
ESCM group: <i>Enterobacter</i> spp, <i>Serratia marcescens</i> , <i>Citrobacter</i> spp, <i>Morganella morganii</i>														

^a *S. aureus* susceptible to methicillin/flucloxacillin denotes susceptibility to cefazolin and amoxicillin-clavulanate

^b *Enterococcus* species are intrinsically resistant to cephalosporins

^c Includes Intermediate (Susceptible, Increased Exposure) results

^d Treatment of uncomplicated urinary tract infections only

Use requires patient-specific Infectious Diseases/Clinical Microbiology approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g. 'The Pink Book'.

\$ Use requires patient-specific Infectious Diseases/Clinical Microbiology/Respiratory Specialist approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g. 'The Pink Book'.

No data or not tested
Colour Interpretation
≥ 90% Susceptible
70 - 89% Susceptible
< 70% Susceptible